Nuclera has expanded its Series C funding round to USD $87 million following a new USD $12 million extension led by Elevage Medical Technologies and Jonathan Milner, alongside existing investors British Business Bank and GK Goh.
The company said the financing will accelerate the integration of antibody expression and binding validation capabilities into its benchtop eProtein Discovery system.
The Cambridge and Boston-based company said the expansion of eProtein Discovery represents a strategic move into AI-enabled protein engineering, supporting the industry’s need for scalable and standardised datasets for next‑generation biologics discovery.
The new capabilities will allow researchers to carry out end‑to‑end expression, purification and binding validation of full‑format antibodies on a single high‑throughput platform.
Since its previous Series C close in 2024, Nuclera has added a membrane protein workflow, expanded its global footprint across APAC and the Middle East and launched a collaboration with Cytiva to accelerate the path from DNA to fully purified proteins. The system has also been installed at Domainex, marking its first CRO implementation.
Michael Chen, CEO and co‑founder of Nuclera, said: “This financing underscores our growing momentum and demonstrates that we are expanding eProtein Discovery into one of the fastest-growing segments of biologics R&D. Scientists increasingly require scalable, high-quality datasets to power AI models in biologics discovery. We are positioning Nuclera to become a foundational platform for the future of protein and antibody engineering, ultimately accelerating therapeutic discovery timelines.”
Michael Wasserman, Chief Operating Officer at Elevage Medical Technologies, explained: “Since our initial investment, Nuclera has made meaningful progress in expanding the capabilities, adoption, and global reach of the eProtein Discovery platform. The extension of the system into full-format antibody expression, purification, and binding validation represents a significant step forward, particularly as biologics discovery becomes increasingly driven by AI-enabled workflows that require scalable, high-quality datasets.”
Jonathan Milner, Chairman of the Nuclera Board of Directors, added: “Nuclera is solving one of the most pressing bottlenecks in biologics discovery – the slow, fragmented, and resource-intensive process of synthesising full-format antibodies.”
Nuclera said the expanded platform will help reduce the time, cost and uncertainty associated with protein expression and purification by combining cell‑free expression systems, digital microfluidics and robust screening data.
